Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.42 |
| ▸ | STAT5B | P51692 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6960268 | 0.94 | F2 (0.41) | F2STAT5BBRD4CA2PAX8 | |
| SCHEMBL6960483 | 0.82 | CNR2 (0.43) | CA2ALDH1A1MAPK1 | |
| SCHEMBL30830665 | 0.81 | PSMD10 (0.39) | F2STAT5BPAX8MEN1KMT2A | |
| SCHEMBL31618103 | 0.79 | CA9 (0.43) | CA2ALDH1A1 | |
| SCHEMBL2879956 | 0.78 | STAT5B (0.38) | F2STAT5BCA2MEN1KMT2A | |
| SCHEMBL30844048 | 0.78 | MAPT (0.44) | CA2ALDH1A1 | |
| SCHEMBL18289526 | 0.78 | CYP19A1 (0.50) | CA2MEN1KMT2A | |
| SCHEMBL15656810 | 0.76 | ACHE (0.52) | BRD4PAX8 | |
| SCHEMBL27542210 | 0.76 | BRD4 (0.46) | BRD4PAX8MEN1KMT2A | |
| SCHEMBL6961246 | 0.75 | CNR2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6562808-B1 | Calcium channel antagonists effective in treating intestinal diseases caused by abnormal acceleration of the contraction of intestinal tracts such as irritable bowel syndrome, without significant cardiac effects | AJINOMOTO CO., INC. (JP) | 2003-05-13 | — | — | US | disclosed |
| EP-1020466-B1 | 5,11-DIHYDRODIBENZ[b,e][1,4]OXAZEPINE DERIVATIVES AND MEDICINAL COMPOSITION CONTAINING THE SAME | AJINOMOTO KK (JP) | 2003-02-19 | — | — | EP | disclosed |
| CN-1278816-A | 5, 11-dihydrodibenzo [ b, e ] [1,4] oxazepine * derivatives and pharmaceutical compositions containing the same | AJINOMOTO KK (JP) | 2001-01-03 | — | — | CN | disclosed |
| EP-1020466-A1 | 5,11-DIHYDRODIBENZ[b,e][1,4]OXAZEPINE DERIVATIVES AND MEDICINAL COMPOSITION CONTAINING THE SAME | Ajinomoto Co., Inc. (JP) | 2000-07-19 | — | — | EP | disclosed |